Vesper Bio
Denmark - CopenhagenBiotechnology
Focus: Vesper Bio is a public biotech company headquartered in Copenhagen, Denmark, focused on developing oral therapies for frontotemporal dementia with additional interests in oncology and neurology. The company operates at the public stage with minimal disclosed operational scale.
Profile data last refreshed 5h ago · AI intelligence enriched 1w ago
Funding Stage
PUBLIC
Open Jobs
6+4 this month
Stable — net +4 jobs in 30d
6 added, 2 removed. Backfill posture.
Should You Work at Vesper Bio?
AI assessmentEarly-stage opportunity with meaningful unmet-need focus, but extreme lack of operational disclosure and clinical evidence should trigger due diligence before committing.
Why Work Here
- Rare disease focus (frontotemporal dementia) offers meaningful impact potential in an underserved neurology space with less competitive talent pressure than mainstream oncology.
Data completeness
1/9 — Limited
Company HealthSolid
Pipeline
Early-stage
0 total
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Open Jobs (6)
Interview Prep Quick Facts
Help build intelligence for Vesper Bio
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.